阻断白细胞介素-6和白细胞介素-8信号传导可抑制人三阴性乳腺癌和胰腺癌细胞的细胞活力、集落形成活性及细胞迁移。
Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
作者信息
Fu Shengling, Lin Jiayuh
机构信息
Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD, U.S.A.
出版信息
Anticancer Res. 2018 Nov;38(11):6271-6279. doi: 10.21873/anticanres.12983.
BACKGROUND/AIM: Interleukin-6 (IL-6) and interleukin-8 (IL-8) play important roles in the progression of triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). This is the first experiment to combine small molecules targeting these two signaling pathways to treat TNBC and PDAC cells.
MATERIALS AND METHODS
Cell viability, colony formation and cell migration assays were conducted when TNBC or PDAC cells were treated with bazedoxifene (targeting IL-6) or reparixin/SCH527123 (targeting IL-8) or their combination.
RESULTS
The combined treatment had a more potent inhibition of cell viability, colony formation and cell migration than monotherapy in TNBC and PDAC cells. The results also showed that the combination of bazedoxifene with SCH527123 seemed to be more effective than that with reparixin in inhibiting cell viability and colony formation of TNBC.
CONCLUSION
Novel drug combinations of bazedoxifene and reparixin, as well as bazedoxifene and SCH527123 may provide more effective treatments for TNBC and PDAC.
背景/目的：白细胞介素-6（IL-6）和白细胞介素-8（IL-8）在三阴性乳腺癌（TNBC）和胰腺导管腺癌（PDAC）的进展中发挥重要作用。这是首次将靶向这两条信号通路的小分子联合用于治疗TNBC和PDAC细胞的实验。
材料与方法
当TNBC或PDAC细胞用巴多昔芬（靶向IL-6）或瑞帕霉素/SCH527123（靶向IL-8）或它们的组合进行处理时，进行细胞活力、集落形成和细胞迁移试验。
结果
联合治疗比单一疗法对TNBC和PDAC细胞的细胞活力、集落形成和细胞迁移具有更强的抑制作用。结果还表明，在抑制TNBC细胞活力和集落形成方面，巴多昔芬与SCH527123的组合似乎比与瑞帕霉素的组合更有效。
结论
巴多昔芬与瑞帕霉素以及巴多昔芬与SCH527123的新型药物组合可能为TNBC和PDAC提供更有效的治疗方法。
Zotero 插件